Gryaznov Sergei 4

What Happened
Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, was granted 400,000 derivative awards (stock options) on May 29, 2026. The Form 4 records the acquisition as 400,000 shares at $0.00 (derivative award), indicating a grant of options rather than a cash purchase or sale. The filing does not list an exercise price or immediate cash value.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-01 (filed within the standard two-business-day reporting window).
• Transaction type/code: Award/Grant (A) — derivative securities (stock options).
• Amount: 400,000 options granted; reported price $0.00 on Form 4 (reflects grant reporting, not exercise price).
• Vesting (footnote F1): 4-year schedule — 25% vests on the first anniversary, remainder vests ratably monthly over the next 36 months.
• Plan: Granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan.
• Shares owned after transaction: Not reported in the provided filing excerpt.
• No indication of a 10b5-1 plan, tax withholding, or immediate cashless exercise included in this filing.

Context
This filing documents a compensation-related grant of options (a derivative award) rather than a market purchase or sale. Such grants give the holder the right to buy common stock in the future (subject to vesting and any exercise price) and do not create immediate proceeds or losses. The vesting schedule ties the award to future service; it’s a routine executive compensation event and should be viewed as informational rather than a direct buy/sell signal.